GlassScriptPhysician profile
Mark S Russo
NPI 1316934326
$49,504.12
in general payments reported to CMS, 2019-2025
39 companies · $3,088 in 2025
The $3,088 reported for 2025 was more than what 92% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $5,315 · 2021: $2,237 · 2022: $3,662 · 2023: $2,016 · 2024: $3,564 · 2025: $3,088.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,749 · Consulting Fee: $1,920.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,748.56 |
| Consulting Fee | $1,920.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $20,166.73 | 2019-2023 | Veltassa, Korsuva |
| Mallinckrodt Enterprises LLC | $9,511.68 | 2019 | |
| Mallinckrodt Hospital Products INC. | $4,779.13 | 2020-2025 | Acthar, Terlivaz |
| Baxter Healthcare | $4,297.29 | 2019-2025 | Renal - Pd, Renal - Chronic, Renal - Acute |
| Novartis Pharmaceuticals Corporation | $1,536.84 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,241.77 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $880.01 | 2019-2025 | Farxiga, Lokelma |
| Akebia Therapeutics INC | $711.00 | 2021-2025 | Vafseo, Auryxia |
| Calliditas Therapeutics US INC. | $707.61 | 2022-2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $509.54 | 2019-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $497.35 | 2019-2025 | Jynarque, Voyxact |
| Glaxosmithkline, LLC. | $478.13 | 2020-2025 | Benlysta |
| Amgen INC. | $469.11 | 2019-2025 | Tavneos, Krystexxa |
| Horizon Therapeutics Plc | $453.40 | 2019-2022 | |
| Gastroklenz, INC. Dba Cloudcath | $400.00 | 2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $396.86 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $350.85 | 2021-2024 | Onpattro, Givlaari |
| Aurinia Pharma U.S., INC. | $240.60 | 2021-2024 | Lupkynis |
| Vantive US Healthcare LLC | $202.53 | 2025 | Renal - Pd |
| Daiichi Sankyo INC. | $192.86 | 2019-2023 | Injectafer |
| Kaneka Medical America LLC | $183.73 | 2019 | |
| Lilly USA, LLC | $183.57 | 2023-2025 | Jardiance |
| Coala Life INC | $153.27 | 2023 | Coala Heart Monitor |
| Nxstage Medical, INC. | $131.75 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.36 | 2022-2025 | Jardiance |
| Ardelyx, INC. | $96.57 | 2023-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $94.53 | 2022-2023 | Verquvo |
| Abiomed | $91.51 | 2024-2025 | Impella |
| Scpharmaceuticals INC. | $75.00 | 2025 | |
| Outset Medical INC | $66.00 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.18 | 2020-2021 | |
| Genzyme Corporation | $47.71 | 2019-2022 | |
| Novo Nordisk INC | $45.34 | 2025 | |
| Shire North American Group INC | $44.63 | 2019 | |
| Alexion Pharmaceuticals, INC. | $35.65 | 2021-2023 | Ultomiris |
| Fresenius USA Marketing, INC. | $30.43 | 2019 | |
| Apellis Pharmaceuticals, INC. | $19.48 | 2025 | Empaveli |
| Cormedix INC. | $14.13 | 2024 | Defencath |
| Nestle Healthcare Nutrition INC. | $12.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Russo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.